Edgewise Therapeutics Inc
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company d… Read more
Edgewise Therapeutics Inc (EWTX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.062x
Based on the latest financial reports, Edgewise Therapeutics Inc (EWTX) has a cash flow conversion efficiency ratio of -0.062x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-34.78 Million) by net assets ($558.65 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Edgewise Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Edgewise Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Edgewise Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Edgewise Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fraport AG
PINK:FPRUF
|
0.130x |
|
CHINA CONCH VENT. HD -01
F:68C
|
N/A |
|
K92 Mining Inc
OTCQX:KNTNF
|
0.088x |
|
Far East Horizon Limited
PINK:FEZHF
|
N/A |
|
Jiangsu Sidike New Materials Sci Te
SHE:300806
|
0.054x |
|
Goodyear Tire & Rubber Co
NASDAQ:GT
|
0.444x |
|
Inaba Denki Sangyo Co.Ltd.
PINK:IBADF
|
N/A |
|
Pandox AB (publ)
PINK:PNDXF
|
0.052x |
Annual Cash Flow Conversion Efficiency for Edgewise Therapeutics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Edgewise Therapeutics Inc from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $459.22 Million | $-109.03 Million | -0.237x | +17.67% |
| 2023-12-31 | $318.83 Million | $-91.95 Million | -0.288x | -89.97% |
| 2022-12-31 | $346.72 Million | $-52.63 Million | -0.152x | -24.31% |
| 2021-12-31 | $274.38 Million | $-33.51 Million | -0.122x | -127.89% |
| 2020-12-31 | $-33.42 Million | $-14.63 Million | 0.438x | -19.53% |
| 2019-12-31 | $-16.85 Million | $-9.17 Million | 0.544x | -- |